About Glioblastoma Multiforme (GBM)
Glioblastoma Multiforme (GBM) is an aggressive primary brain tumor affecting mostly adults, with a median age at diagnosis of 55 years.
Current ‘standard-of-care’ treatment regimen typically consists of surgery to reduce the tumor mass to the extent safely feasible, followed by radiation therapy and chemotherapy.
About the GLASS-ART Trial
At the direction of Bradmer Pharmaceuticals, the trial sponsor, the Phase III GLASS-ART Trial has been closed to further patient enrollment.
The company continues to support and track the progress of all patients currently enrolled in the GLASS-ART Trial.
For more information, please consult resources available at the company website, BradmerPharma.com, or send email to info@bradmerpharma.com.
About Neuradiab®
Neuradiab® is an investigational drug currently in the clinical testing process established by the U.S. Food and Drug Administration (FDA) for the evaluation of new drugs.
The GLASS-ART Trial is a Phase III clinical trial testing Neuradiab®. The acronym GLASS-ART stands for:
GBM Locoregional Agent Survival Study -
Anti-tenascin Radiolabeled antibody Therapy.
The purpose of the GLASS-ART Trial is to determine if adding the study drug Neuradiab® to standard treatment regimen, which is composed of surgery followed by radiation and chemotherapy treatment, will be a better treatment than standard therapy alone.